University of Ioannina
Ανάλυση τεκμηρίων στον ορθοκολικό καρκίνο και αντίκτυπος στην κλινική πράξη
Abstract
dc:descriptionIntroduction Colon and rectal cancer are represented as a single entity in studies. However, they have different anatomical characteristics, different microbiota, different disease spread patterns, and different oncological therapeutic approaches. In addition, the occurrence of colorectal cancer in young adults under 50 years old (early-onset colorectal cancer) is a rapidly evolving phenomenon that requires a better understanding of causal relationships and management. Furthermore, regarding the treatments used, the effectiveness of aggressive and less aggressive treatments (triplet vs doublet) is different. Of course, there are also targeted therapies, one of which is against the KRAS G12C mutation. Objectives To describe the clinical and biochemical characteristics of young adult patients(till 50 years old) with metastatic colon or rectal cancer and to assess their possible effect on survival depending on tumor location. In addition, patients with heterozygous Lynch syndrome, dMMR/MSS, and colorectal cancer, should be investigated and their response to immunotherapy should be examined and whether this is related to tumor location. Moreover, to examine the efficacy of therapies targeting the KRAS G12C mutation in patients with metastatic colon and rectal cancer. Materials and methods-Results Study 1: the medical records of the Oncology Department of the University Hospital of Ioannina were searched to identify patients up to 50 years of age with metastatic colorectal cancer and their clinical and biochemical characteristics were examined. Forty-five patients were identified, of whom 26 were diagnosed with colon cancer and 19 with rectal cancer. A positive family history of cancer was found to be statistically more frequent in patients with colon cancer (p = 0.025). Although significant differences were observed in absolute neutrophil count, lymphocyte count, and platelet/lymphocyte ratio during the treatment of patients with colon versus rectal cancer, these biochemical differences did not translate into statistically significant differences, either in terms of progression-free survival (PFS) or overall survival (OS). Study 2: patients with Lynch syndrome and colorectal cancer MSS were investigated in the medical records of the Oncology Department and after a systematic review of the literature of electronic medical libraries, major oncology conferences and oncology scientific journals. Four patients (aged 16-51 years) with MSH6 mutation and MSS tumor were identified, one from the medical records and three from the systematic review of the literature. Immunotherapy was used in three of them, as one received adjuvant chemotherapy. The use of immunotherapy resulted in disease progression in two patients and in one partial response. No complete response was observed. Study 3: a systematic review of databases, major conferences and scientific journals was performed for the efficacy of triplet vs doublet. We ended up with 9 studies. An attempt to contact the main authors was made. Only one research group accepted. Therefore, we were unable to proceed with further analyses. Study 4: A systematic review of databases, major conferences, and scientific journals was performed to determine the efficacy of therapies targeting the KRAS G12C mutation (monotherapies and combination therapies) in patients with metastatic colon and rectal cancer. A meta-analysis of proportions was performed. A total of 19 studies were identified. 863 patients were analyzed. Conclusions Study 1: in patients under 50 years of age with EOCRC, colorectal cancer was more frequently associated with a family history of gastrointestinal cancer compared with rectal cancer. In our study, there were no differences in survival between the two groups. Study 2: patients with Lynch syndrome and colorectal cancer MSS were found to be underrepresented in the literature and their likelihood of responding to immunotherapy with immune checkpoint inhibitors seems minimal. Study 3: due to the inability to gather data, we were unable to reach any conclusions. Study 4: the use of targeted therapy against the KRASG12C mutation in metastatic colon and rectal cancer appears promising. However, there was heterogeneity between the studies analyzed.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kapoulitsa, Fani
- Καπουλίτσα, Φανή
Subjects
dc:subject × 15Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/59022